ABIONYX Pharma SA (EPA:ABNX)
France
· Delayed Price · Currency is EUR 1.228
-0.042 (-3.31%)
Apr 1, 2025, 12:22 PM CET
ABIONYX Pharma Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 4.6 | 4.64 | 5.25 | 0.68 | - | Upgrade
|
| Revenue Growth (YoY) | -0.86% | -11.65% | 678.07% | - | - | Upgrade
|
| Cost of Revenue | 3.7 | 4.02 | 4.62 | 0.42 | - | Upgrade
|
| Gross Profit | 0.9 | 0.62 | 0.64 | 0.26 | - | Upgrade
|
| Selling, General & Admin | 3.4 | 2.61 | 3.66 | 2.34 | 1.27 | Upgrade
|
| Research & Development | 1.9 | 1.52 | 1.11 | 3.84 | 1.7 | Upgrade
|
| Other Operating Expenses | - | -0.1 | -0.02 | 0.04 | - | Upgrade
|
| Operating Expenses | 5.3 | 4.03 | 4.75 | 6.21 | 2.97 | Upgrade
|
| Operating Income | -4.4 | -3.41 | -4.11 | -5.95 | -2.97 | Upgrade
|
| Interest Expense | -0.1 | -0.02 | -0.06 | -0.01 | - | Upgrade
|
| Interest & Investment Income | 0.2 | 0.06 | 0.01 | 0 | 0.06 | Upgrade
|
| Currency Exchange Gain (Loss) | - | -0.04 | 0.04 | -0.02 | 0.04 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.1 | -0.2 | -0.08 | 0.15 | - | Upgrade
|
| EBT Excluding Unusual Items | -4.4 | -3.61 | -4.21 | -5.82 | -2.87 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 0.09 | - | - | 0.09 | Upgrade
|
| Other Unusual Items | - | - | - | - | 0.9 | Upgrade
|
| Pretax Income | -4.4 | -3.52 | -4.21 | -5.82 | -1.89 | Upgrade
|
| Net Income | -4.4 | -3.52 | -4.21 | -5.82 | -1.89 | Upgrade
|
| Net Income to Common | -4.4 | -3.52 | -4.21 | -5.82 | -1.89 | Upgrade
|
| Shares Outstanding (Basic) | - | 29 | 28 | 25 | 23 | Upgrade
|
| Shares Outstanding (Diluted) | - | 29 | 28 | 25 | 23 | Upgrade
|
| Shares Change (YoY) | - | 4.95% | 12.41% | 5.92% | 11.21% | Upgrade
|
| EPS (Basic) | - | -0.12 | -0.15 | -0.23 | -0.08 | Upgrade
|
| EPS (Diluted) | - | -0.12 | -0.15 | -0.23 | -0.08 | Upgrade
|
| Free Cash Flow | -3.6 | -3.8 | -3.52 | -6.86 | -0.7 | Upgrade
|
| Free Cash Flow Per Share | - | -0.13 | -0.13 | -0.28 | -0.03 | Upgrade
|
| Gross Margin | 19.56% | 13.32% | 12.11% | 38.37% | - | Upgrade
|
| Operating Margin | -95.65% | -73.53% | -78.24% | -881.78% | - | Upgrade
|
| Profit Margin | -95.65% | -75.82% | -80.08% | -862.52% | - | Upgrade
|
| Free Cash Flow Margin | -78.26% | -81.94% | -67.10% | -1016.00% | - | Upgrade
|
| EBITDA | - | -3.29 | -3.99 | -5.83 | -2.95 | Upgrade
|
| EBITDA Margin | - | -70.91% | -75.91% | - | - | Upgrade
|
| D&A For EBITDA | - | 0.12 | 0.12 | 0.12 | 0.02 | Upgrade
|
| EBIT | -4.4 | -3.41 | -4.11 | -5.95 | -2.97 | Upgrade
|
| EBIT Margin | -95.65% | -73.53% | -78.24% | - | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.